An open-label study to explore the efficacy of NMK36 single-dose (i.v.) injection for diagnosis of regional lymph node metastasis in subjects with prostate cancer

Trial Profile

An open-label study to explore the efficacy of NMK36 single-dose (i.v.) injection for diagnosis of regional lymph node metastasis in subjects with prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Nihon Medi-Physics
  • Most Recent Events

    • 24 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top